Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
VYNE
Stock Latest News
Ratings
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study
23h ago
VYNE
Premium
Ratings
Promising Outlook for VYNE Therapeutics: Buy Rating Backed by Repibresib’s Potential in Vitiligo Treatment
6d ago
VYNE
Premium
Ratings
VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating
7d ago
VYNE
Premium
The Fly
H.C. Wainwright ‘encouraged’ by VYNE Therapeutics VYN202 update
7d ago
VYNE
Premium
Ratings
Optimistic Outlook for VYNE Therapeutics Amid Promising VYN202 Program Developments
7d ago
VYNE
Premium
The Fly
VYNE Therapeutics provides program update on VYN202 following clinical hold
7d ago
VYNE
Premium
Company Announcements
VYNE Therapeutics Reports Q1 2025 Financial Results
2M ago
VYNE
Premium
Ratings
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
2M ago
VYNE
Premium
The Fly
VYNE Therapeutics reports Q1 EPS (20c) vs (15c) last year
2M ago
VYNE
Premium
Ratings
Optimistic Buy Rating for VYNE Therapeutics Amid Clinical Challenges and Promising Developments
3M ago
VYNE
Premium
The Fly
VYNE Therapeutics price target lowered to $4.50 from $5.75 at H.C. Wainwright
3M ago
VYNE
Premium
The Fly
VYNE Therapeutics announces FDA placed clinical hold on study on VYN202
3M ago
VYNE
Premium
Company Announcements
VYNE Therapeutics Reports Progress in Clinical Trials
4M ago
VYNE
Premium
Ratings
Buy Rating for VYNE Therapeutics Driven by Strong Financial Health and Promising Pipeline Developments
4M ago
VYNE
Premium
Ratings
VYNE Therapeutics: Strong Financials and Promising Clinical Developments Reinforce Buy Rating
4M ago
VYNE
Premium
The Fly
VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year
4M ago
VYNE
Premium
Ratings
VYNE Therapeutics: Promising Pipeline and Strategic Focus Drive Buy Rating
4M ago
VYNE
Premium
Ratings
Positive Outlook on VYNE Therapeutics Driven by Promising VYN202 Developments and Selective BD2 Targeting
5M ago
VYNE
Premium
Ratings
VYNE Therapeutics Receives Buy Rating: Promising Clinical Advances in Plaque Psoriasis Treatment
5M ago
VYNE
Premium
The Fly
VYNE Therapeutics announces dosing of first patient in Phase 1b trial of VYN202
5M ago
VYNE
Premium
The Fly
VYNE Therapeutics completes enrollment in Phase 2b trial on VYN201
6M ago
VYNE
Premium
The Fly
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data
7M ago
VYNE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
